Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs
Executive Summary
FDA’s focus on the optimal dose for AstraZeneca’s medullary thyroid cancer treatment vandetanib could portend a harder line in ensuring that appropriate dosing for new cancer drugs is established before approval.
You may also be interested in...
Expanded Access Opens Window For Dose Optimization Studies In Cancer
The period after completion of pivotal trials but ahead of FDA approval provides an opportunity for oncology drug sponsors to conduct badly needed dose comparison trials, a multi-stakeholder panel says at the annual Conference on Clinical Cancer Research.
Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety
FDA’s review of Novartis’ sBLA for Ilaris (canakinumab) in gout reflects an evolving agency philosophy toward dose optimization for biologic agents – an approach that is likely to require more sponsor attention to pre-approval dose exploration studies.
Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety
FDA’s review of Novartis’ sBLA for Ilaris (canakinumab) in gout reflects an evolving agency philosophy toward dose optimization for biologic agents – an approach that is likely to require more sponsor attention to pre-approval dose exploration studies.